Secukinumab is prescribed for:
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Dermatologic autoimmune conditions
Generic Name: Secukinumab
Brand Names: Cosentyx
Secukinumab is an IL-17A inhibitor biologic for psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Secukinumab is prescribed for:
Common side effects:
Serious side effects:
Secukinumab is a monoclonal antibody that blocks IL-17A, a key cytokine in psoriatic disease.
Achieves PASI 90 (90% skin clearance) in many psoriasis patients.
May worsen or trigger inflammatory bowel disease. Avoid in patients with active IBD.
Learn more at MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Osteoarthritis, a common degenerative joint disease, causes pain, stiffness, and reduced motion due to cartilage breakdown from aging, genetics, obesity, injuries, or repetitive stress.
Ulcerative colitis is a chronic inflammatory bowel disease causing ulcers and inflammation in the colon and rectum, driven by immune dysfunction, genetics, and environmental factors, leading to symptoms like diarrhea and abdominal pain.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Secukinumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.